Abstract 171P
Background
To investigate the effect of both prostate volume and serum testosterone changes on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy.
Methods
A total of 167 patients who received androgen deprivation therapy for prostate cancer treatment from January 2010 to August 2020 were enrolled in this retrospective study. Changes in the International Prostate Symptom Score (IPSS) in the patient groups stratified by prostate volume and the amount of testosterone reduction were assessed every 4 weeks until 12 weeks after androgen deprivation therapy initiation. Longitudinal mixed models were used to assess the adjusted effects of prostate volume and testosterone reduction on IPSS change.
Results
All mean values of IPSS-total score (IPSS-total), voiding subscore (IPSS-vs), and storage subscore (IPSS-ss) significantly decreased from baseline to week 12 in both patients with small (<33 mL) and large (≥33 mL) prostates. The mean values of IPSS-total, IPSS-vs, and IPSS-ss similarly decreased in patients with large prostate with a baseline IPSS-total of ≥13. However, in those with small prostate, IPSS-ss specifically remained unchanged, while IPSS-total and IPSS-vs significantly decreased. In addition, only in patients with small prostate (<33 mL), patients with lesser testosterone reduction (<Δ400 ng/dL) showed greater improvement in IPSS-ss by 6.3% compared with those with greater testosterone reduction (≥ Δ400 ng/dL).
Conclusions
Although androgen deprivation therapy generally improves lower urinary tract symptoms, it may not improve storage symptoms in patients with relatively small prostate and greater testosterone reduction. Our finding suggests that testosterone may influence lower urinary tract symptoms in these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
197P - The risk of uterine cervical cancer in inflammatory bowel disease: An updated systematic review and meta-analysis
Presenter: Hee Man Kim
Session: Poster viewing 03
198P - Geographic and demographic access to brachytherapy in India, with a special emphasis on gynaecological cancers
Presenter: Abhishek Krishna
Session: Poster viewing 03
199P - Prevalence of cervical cancer in Uzbekistan: A population based study
Presenter: Sayde Djanklich
Session: Poster viewing 03
200P - A retrospective institutional analysis on gynecological malignant mixed Mullerian tumors
Presenter: Monik Patel
Session: Poster viewing 03
201P - Immunotherapy in advanced mismatch repair deficiency endometrial cancer: A real-world single center experience
Presenter: Amit Rauthan
Session: Poster viewing 03
203TiP - Autophagy as a target for therapy in ovarian cancer: A phase II randomized trial with biomarker correlation (ATOC Trial)
Presenter: Luxitaa Goenka
Session: Poster viewing 03
210P - Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays
Presenter: Lei Chen
Session: Poster viewing 03
211P - Chemotherapy delivery time affects anti-lymphoma treatment outcome in a sex-dependent manner
Presenter: Yeonsoo Park
Session: Poster viewing 03